MedTrace Logo

Use of NPSP558 in the Treatment of Hypoparathyroidism

NCT00732615 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2021-06-03

Study results available
· View outcomes & findings →

Summary

Use of PTH (1-84) a recombinant hormone in escalating doses for the treatment of adults with hypoparathyroidism. The use of PTH should result in a decrease of calcium and vitamin D supplements.

Conditions

  • Hypoparathyroidism

Interventions

DRUG

Placebo

Placebo for subcutaneous injection

DRUG

NPSP558

Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily

Sponsors & Collaborators

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-18
Primary Completion
2011-09-28
Completion
2011-09-28

Countries

  • United States
  • Belgium
  • Canada
  • Denmark
  • France
  • Hungary
  • Italy
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00732615 on ClinicalTrials.gov